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 [Abstract] 
Key content
	Routine diagnostic hysteroscopy under general anaesthesia is an anachronism.
	Evidence-based RCOG guidance should be followed to ensure best practice in outpatient hysteroscopy.
	The role of hysteroscopy in the diagnostic work-up of abnormal bleeding and reproduction remains unclear and further research is required to elucidate where it can be used most cost-effectively. 
Learning objectives
	A ‘no touch’ vaginoscopic technique should be employed routinely as this approach reduces pain during diagnostic rigid outpatient hysteroscopy and facilitates operative procedures by improving manipulation of miniature endoscopic equipment.
	A contemporary outpatient hysteroscopy service should be able to provide surgical treatments for uterine polyps, small fibroids, lost coils, minor uterine anomalies, menstrual disorders and permanent contraception. 
Ethical issues
	Can we justify subjecting women, especially those with significant medical co-morbidities, to the risks and inconvenience of general anaesthesia for hysteroscopic procedures?
Keywords:	 ‘see and treat’/ one-stop / hysteroscopy / outpatients
Introduction
Direct visualisation of the vagina, cervix and uterine cavity with the aid of an endoscope does not just facilitate diagnosis of disease, but also provides therapeutic possibilities, either directly (‘hysteroscopic surgery’) or indirectly (directing ‘blind procedures’ including global endometrial ablation). Such interventions were traditionally the domain of hospital day-case wards with procedures performed under general anaesthesia. This is no longer the case. The advent of small diameter modern hysteroscopes (≤5.5 mm), allied with the miniature 5–7 Fr ancillary instruments (mechanical instruments: scissors; graspers; biopsy cups; bipolar electrodes, e.g. Versapoint™ [Gynecare, Ethicon, Menlo Park, CA, USA]; morcellators: TRUCLEAR™ [Smith & Nephew, Andover, MA, USA], MyoSure® [Hologic, Marlborough, MA, USA]; and female sterilisation systems: Essure® [Conceptus Inc., Mountain View, CA, USA]) has led the paradigm shift of surgical interventions being undertaken in an ‘inpatient’ general anaesthetic setting to an ‘outpatient’ environment with recourse to local anaesthesia if necessary. Thus, the modern gynaecologist is not restricted to efficient outpatient diagnosis using hysteroscopy, transvaginal ultrasound and endometrial biopsy, but can institute minimally invasive therapeutic interventions in an equally proficient manner. As a result, the philosophy of efficient, safe and convenient ‘see and treat’, ‘one stop’ gynaecology in an ambulatory setting – the patient ‘ambulates’ in and ‘ambulates’ out – has come of age. 
We will discuss in this article the advances in outpatient hysteroscopy, taking account of the evidence to support interventions and recent best practice guidance.
Conducting outpatient hysteroscopy
A Green-top joint British Society for Gynaecological Endoscopy/ Royal College of Obstetricians and Gynaecologists (BSGE/RCOG) guideline addressing best practice in outpatient hysteroscopy has been recently published.1 The aim of the guideline is to provide clinicians with up-to-date, evidence-based information regarding outpatient hysteroscopy, with particular reference to minimising pain and optimising women’s experience. Thus, by standardising best practice and identifying areas where evidence is lacking, we can hope to optimise both current and future patient experience. Box 1 summarises the key recommendations for best practice in outpatient hysteroscopy and Box 2 summarises the key points of ‘no touch’ vaginoscopic hysteroscopy which should be the default technique in an outpatient environment. ADDIN REFMGR.CITE 2–4
Indications for diagnostic outpatient hysteroscopy
The main indications for diagnostic hysteroscopy are shown in Box 3. The place of outpatient hysteroscopy (OPH) as a third-line test after transvaginal ultrasound (TVU) and endometrial biopsy in the diagnostic work-up of women with postmenopausal bleeding (PMB) is relatively well defined.5 However, for the most part, whereas there are synergies between the available tests, there is also some crossover in the information provided. For example, the place of OPH relative to TVU, endometrial biopsy and saline infusion sonography in heavy menstrual bleeding (HMB) and non-menstrual bleeding is unclear. By contrast with a PMB population, women with HMB do not have a ‘normal’ endometrial thickness and the risk of endometrial cancer or atypia is low. Thus, the utility of routine TVU, endometrial biopsy and OPH is questionable and this is borne out in the management algorithm produced by the National Institute for Health and Clinical Excellence (NICE).6 However, women with HMB can have endometrial hyperplasia, submucous fibroids of various grades and sizes, uterine polyps, uterine anomalies including uterine fibroids and adenomyosis and benign adnexal masses. Non-diagnosis of these pathologies prevents implementation of the many effective medical and surgical treatments for HMB and is therefore likely to result in prolonged suffering, reduced health-related quality of life and absenteeism from work with costs to the economy. Current research involving decision analytical modelling hopes to provide us with some answers as to which testing strategies are the most cost-effective in HMB.7
Before leaving diagnostic indications, it is worth considering the wider place of OPH in the management of menstrual disorders, aiding safe intrauterine instrumentation (e.g. endometrial biopsy, levonorgestrel intrauterine system [LNG-IUS] insertion) and treatment planning. The latter role of OPH is often overlooked. For example, OPH may be useful in estimating the likely response of symptoms to minimally invasive treatments with LNG-IUS and endometrial ablation, based upon a hysteroscopic assessment of the endometrium, uterine size, capacity, shape and regularity. The test can also help determine the most appropriate treatment setting (i.e. outpatient versus day-case under general anaesthesia), based upon patients’ tolerance of the procedure and any adverse anatomical factors. Similarly, in the case of submucous fibroid(s), OPH in conjunction with TVU allows an assessment of treatment setting and need for endometrial preparation based upon the size, vascularity, number and location. It aids patient counselling as to the likelihood of needing repeated surgeries (2/3 stage resections) and the probability of symptomatic relief. Thus, the woman  can make a more informed decision as to whether to opt for conservative hysteroscopic surgery or proceed to hysterectomy. 
Operative hysteroscopy 
Polyps
The removal of uterine polyps appears to confer benefit in terms of resolving symptoms and obtaining tissue for histological examination. ADDIN REFMGR.CITE 8–11 Technological advances in imaging have resulted in better image quality, portability and accessibility, improving the detection rate of focal uterine pathologies. Improvements in hysteroscope design and ancillary instrumentation coupled with enhanced visualisation, due to improvements in fibre optics and digital imaging, have enabled polyps to be removed under direct hysteroscopic vision in an outpatient setting. Mechanical instruments designed to pass down 5 and 7 Fr operating channels have been used successfully,12 but their utility is affected by their size and relative fragility. In the late 1990s the development of bipolar intrauterine electrosurgical systems (e.g. Versapoint™ bipolar electrosurgical system) facilitated rapid resection of focal uterine lesions in a saline conducting medium. ADDIN REFMGR.CITE 13,14 It soon became clear that these rapid and versatile electrosurgical approaches offered a wider repertoire of office treatments including treatment for fibroids, adhesions and uterine anomalies in addition to endometrial polyps15 and have superseded mechanical approaches (Figure 1).
Polyps within the uterus can be fibrous or glandular, pedunculated or sessile, single or multiple and vary in size from small with minimal uterine cavity distortion to large, filling the whole cavity. Location within the cavity can be a challenge especially fundally (due to difficulty accessing the base) or isthmically (due to restrictions of movement) sited lesions. Miniature hysteroscopic morcellators, which require a specific hysteroscope with an offset eyepiece, are the latest technologies to be introduced, e.g. Truclear™ (Figure 2) and MyoSure®. They can be used in the outpatient setting to simultaneously remove and retrieve polyps and submucous fibroids16 and appear to be especially useful in removing larger, fundally sited and multiple pathologies. Concerns over inability to establish histopathological diagnoses from morcellated specimens appear to be unfounded.17 The techniques available for outpatient uterine polypectomy are summarised in Table 1. 
The current literature on these outpatient hysteroscopic techniques has demonstrated safety and feasibility, but evidence of effectiveness, patient acceptability and cost-effectiveness is lacking. ADDIN REFMGR.CITE 14,18–20 A multicentre randomised controlled trial (RCT) has randomised more than 500 women either to outpatient with or without local anaesthesia treatment or to day-case removal under general anaesthesia to compare effectiveness, cost-effectiveness and acceptability between treatment settings.21 These patients, as well as 400 non-randomised additional women who expressed a definite preference for treatment setting, will also allow effectiveness and acceptability of treatments to be compared according to type of abnormal bleeding, menopausal status and treatment technique. In time, therefore, we should have more idea as to how best to treat uterine polyps and whom we should treat.
Fibroids
Submucous fibroids are commonly found in association with menstrual and reproductive problems. Can we remove them hysteroscopically both safely and in entirety or do we offer repeat treatments? Do we need to prepare the endometrium with associated cost and morbidity? Do we need to remove the ‘whole’ fibroid or just ‘normalise’ the contour of the uterine cavity (allowing any residual fibroid to spontaneously extrude) reducing risk of inadvertent uterine perforation and visceral injury? Appropriate diagnostic work-up and consideration of patient views are key to choosing how best to approach the management of uterine fibroids.
The removal of most intracavity fibroids requires general anaesthetic and often larger diameter hysteroscopes with their associated advantages of better visualisation with improved illumination and efficient continuous flow systems as well as easier removal of treated fibroid tissue. However, it is not uncommon for failed removal of polyps under general anaesthetic by curettage to be subsequently removed in the outpatient setting by excising these misdiagnosed grade 0 fibroids using bipolar electrosurgery.22 Smaller, sessile fibroids can also be ablated in the office setting. Even if, for most submucous fibroids, larger diameter resectoscopes are optimal, outpatient hysteroscopic assessment is key; it allows an assessment of treatment setting and need for endometrial preparation, based upon the size, vascularity, number and location of myomas, to be assessed. The role of preliminary incision of the ‘capsule’ of mucosa overlying the submucous fibroid precipitating expulsion of the fibroid into the uterine cavity (e.g. changing a grade 1 to a grade 0 submucous fibroid,23 thereby ‘preparing’ the fibroid for subsequent resection under general anaesthesia, is unclear.
Adhesions, septae and hypoplastic uteri
Hysteroscopic adhesiolysis can be achieved with scissors or Versapoint® diathermy in an outpatient setting where scar tissue is filmy and cavity distortion minimal.24 However, published data are lacking for the safety and feasibility of plastic operations on the uterus in an outpatient, local anaesthetic setting.
Endometrial ablation
The development of ‘second-generation’ miniature, semi-automated ablative technologies has allowed the concept of outpatient local anaesthetic endometrial ablation to be progressed (Figure 3). In the few centres able to offer both treatment environments, outpatient local anaesthetic ablation is as popular as traditional day-case general anaesthetic settings.25 Several observational studies have addressed the feasibility of outpatient local anaesthetic ablation for various technologies: HydroThermAblator System® (Boston Scientific Corp., Natick, MA, USA),26 Thermachoice® Endometrial Ablation (TEA) (Gynecare Inc., Somerville, NJ, USA), ADDIN REFMGR.CITE 27,28 Thermablate EAS™ (Idoman Ltd, Dublin, Ireland),29 NovaSure® bipolar system (RFA) (Hologic, Marlborough, MA, USA).30 There are also some RCTs comparing outpatient local anaesthetic ablation with day-case inpatient general anaesthetic settings: TEA31 and Microwave Endometrial Ablation (MEA) system (Microsulis Medical Ltd, Hampshire, UK). ADDIN REFMGR.CITE 32 For the first time an RCT has been conducted and published directly comparing two of the leading second generation ablative technologies in this ‘novel’ outpatient local anaesthetic setting.33 The ‘COAT’ trial showed that both thermal balloon ablation using the TEA and radiofrequency impedance-controlled endometrial ablation using the RFA system were safe, acceptable and effective in this setting. The RFA procedure was significantly quicker, but no conclusive differences in pain or acceptability were identified between technologies. Rates of amenorrhoea were higher with RFA at all time points post-surgery compared with TEA, but these differences only reached statistical significance at 12 months in favour of RFA. There were no differences in health-related quality of life between treatment modalities but it was significantly improved following both treatments. Only one woman in each treatment arm had undergone a hysterectomy at 12 months.
Whereas the majority of women undergoing the outpatient ablation would recommend it to a woman with a similar problem (82%), 13% of women found the procedure unacceptable.33 We need to define more clearly the women most likely to have a positive and effective outpatient experience. In addition to selecting the ‘right’ patients, we need also to concentrate our efforts on reducing procedure-related pain by manipulating analgesic, anaesthetic (topical, intracervical and delayed paracervical blocks) and sedative regimens.24 The use of intramyometrial injection of local anaesthesia under direct hysteroscopic guidance in the outpatient setting has been recently advocated, the so-called ‘focal–local’.34
Hysteroscopic sterilisation
Outpatient hysteroscopic sterilisation offers women long-term, non-hormonal, effective, irreversible contraception without the need for surgical incisions or anaesthesia, thereby avoiding the small but significant risks of day-case, laparoscopic surgery.35 Although it has long been recognised that the transcervical route to occluding the tubal ostia offers many potential advantages, it is only relatively recently that a technique has become established in clinical practice. The Essure® permanent birth control system is now widely used across Europe, North America and Australasia with more than 500 000 procedures being performed (Figure 4). The procedure involves placing a micro-insert, consisting of a stainless steel inner coil with polyester fibres and a super-elastic nitinol outer anchoring coil, into the intramyometrial portion of each fallopian tube. This is done via a fine delivery catheter which is passed down the 5 Fr operating channel of a 30° 5–5.5 mm continuous flow rigid hysteroscope. The procedure can be performed in the majority of women vaginoscopically using normal saline distension, without local anaesthesia and is completed in 5–10 minutes. The majority of women are discharged home within 1 hour.36 Occlusion of the narrow tubal lumen takes up to 3 months as the polyester fibres cause an inflammatory reaction with tissue ingrowth into the micro-insert and subsequent blockage of the fallopian tube. Confirmatory radiology is scheduled at 3 months to confirm the adequacy of sterilisation; satisfactory device placement is checked by abdominal X-ray or transvaginal ultrasound scan in the 85% of procedures considered straightforward, and the remainder undergo more invasive hysterosalpingogram to confirm tubal occlusion.37 In the last decade since its introduction, the feasibility, ADDIN REFMGR.CITE 36,38 as well as the qualitative39 and economic ADDIN REFMGR.CITE 40,41 benefits, of hysteroscopic sterilisation using the Essure® system have been widely demonstrated. Women must be informed to continue using additional contraception until the results of radiological testing are available.
Successful bilateral device placement rates vary but are consistently >90% and in many centres >95% ADDIN REFMGR.CITE 36,41–43 for techniques. No pregnancies have been reported from the original pivotal trial of Essure®43 and the effectiveness of the Essure® system is reported to be better than laparoscopic sterilisation44 with 5-year success rate of 99.7% from the literature45 supported by data from commercial use (748 pregnancies reported/497 305 kits distributed worldwide; 99.9%)46 although the latter is likely to be an underestimate. Longer term data pertaining to cumulative pregnancy rates and complications are needed for the Essure® technology to allow a fair comparison against laparoscopic approaches. 
Conclusions
Outpatient hysteroscopy confers many advantages over day-case procedures including safety, efficiency, convenience, and cost-effectiveness. ADDIN REFMGR.CITE 24,47,48 In the UK in 2010, a total of 71 130 diagnostic hysteroscopies were performed under general anaesthetic, representing 70% of all diagnostic hysteroscopies. This anachronistic 7:3 ratio needs addressing urgently with investment in ambulatory infrastructure and training, and change in mentality of practising clinicians. An 80% outpatient target for all diagnostic hysteroscopies performed as primary procedures should become mandatory and a 90% target is readily achievable with the correct referral pathways and infrastructures in place. As evidence supporting outpatient intervention accumulates, it is likely that funding of health services will incentivise best practice and drive necessary changes in service delivery. In addition to simple diagnostic procedures, there is mounting evidence to support the use of outpatient therapeutic procedures, namely removal of focal uterine anomalies, ADDIN REFMGR.CITE 14,49 LNG-IUS insertion and retrieval, endometrial ablation,31–33 and female sterilisation. ADDIN REFMGR.CITE 36,42 Further publications from major trials in this field are expected to energise the expansion of ambulatory hysteroscopic services, which appear to be underdeveloped in most UK units. The recent RCOG report examining the future delivery of obstetrics and gynaecology50 recommended devolving some traditional aspects of gynaecological practice to a community-based setting. Those hospitals with established or developing ambulatory diagnostic and therapeutic hysteroscopy services will be in a position to engage and collaborate with local Primary Care Trusts (PCTs) for optimising gynaecological service delivery. By contrast, those hospitals neglecting such services will become vulnerable to losing substantial parts of their traditional gynaecological patient referral base. Evidence, economics and politics demonstrate that now is the time to engage in outpatient ‘see and treat’ hysteroscopy.
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Box 1. Summary of recommendations for best practice in outpatient hysteroscopy
1.	All gynaecology units should provide a dedicated outpatient hysteroscopy service which is appropriately sized, equipped and staffed and located outside of the formal operating theatre setting. The healthcare professional(s) should have the necessary skills and expertise to carry out diagnostic and/or therapeutic outpatient hysteroscopy.
2.	Written patient information should be provided before the appointment and consent for the procedure should be taken.
3.	Women without contraindications should be advised to consider taking standard doses of NSAIDs 1 hour before their appointment, but routine use of opiate analgesia should be avoided.
4.	Routine cervical preparation before outpatient hysteroscopy should not be used unless dilatation beyond Hegar 6 is anticipated.
5.	Miniature hysteroscopic systems (≤4 mm outer diameter) should be used for diagnostic outpatient hysteroscopy. Choice of hysteroscope (e.g. flexible or rigid; 0° or fore-oblique distal lenses) should be left to the discretion of the operator.
6.	Carbon dioxide or normal saline can be used as distension media for diagnostic outpatient hysteroscopy, but normal saline should be used for operative procedures.
7.	Routine, blind cervical dilatation should be avoided. 
8.	Topical application of local anaesthetic to the ectocervix should be considered where a cervical tenaculum is necessary. Routine administration of intracervical or paracervical local anaesthetic should be used where larger diameter hysteroscopes are being employed (outer diameter >5 mm) and where the need for cervical dilatation is anticipated (e.g. cervical stenosis). Standard protocols regarding the type, maximum dosage and route of administration of anaesthesia should be implemented.
9.	Conscious sedation should not be routinely used in outpatient hysteroscopic procedures.
10.	Vaginoscopy (avoiding the use of a vaginal speculum or cervical instrumentation) should be the standard technique for outpatient hysteroscopy.




Box 2. Vaginoscopic ‘no-touch’ technique
The technique
1.	Place the hysteroscope into the vagina and allow the distension media to flow in and distend the vagina.
2.	Advance the scope towards the posterior fornix and look for the cervix. If not immediately visible, work slowly backwards from the vault, angling the hysteroscope upwards as you go (most uteri are anteverted) and sweeping side to side until you identify the cervix and find the external os.
3.	Steer the hysteroscope into the cervical os, along the canal and into the uterine cavity under direct vision. 
4.	Directed biopsies can be taken using a biopsy cup via the operating channel of a rigid hysteroscope, or an H Pipelle can be used to take a global biopsy through the hysteroscopic sheath.2,3
Tips to help identify the cervix vaginoscopically
	Mucus, blood or coil threads training from the cervical os can be followed to locate the cervix.
	A 30° angled hysteroscope makes it easier to identify the cervix.
	If the cervix is difficult to locate consider eccentric placement, a deficient cervix flush with the vault, an acutely retroverted uterus with an anterior placed cervical os, or uterine prolapse with the cervix sited close to the introitus.
	If you still cannot identify the cervix, perform a digital examination to determine its position within the vagina.
Advantages
	Vaginoscopy is significantly more comfortable for the patient than a hysteroscopy using a speculum, tenaculum and local anaesthesia and it does not increase the number of failed procedures.4
	It offers greater manoeuvrability for the operator as they are not restricted by the speculum. This is particularly useful when women have a raised body mass index, acutely flexed uteri or when close approximation of the hysteroscope to focal pathologies or access the tubal ostia for sterilisation is required.




Box 3. Indications for diagnostic outpatient hysteroscopya
Abnormal uterine bleeding
	Postmenopausal bleeding with an endometrial thickness >4 mm or irregular endometrium on TVU or a non-diagnostic endometrial biopsy or on tamoxifen
	Recurrent postmenopausal bleeding
	Unscheduled/intermenstrual bleeding with an abnormal endometrium on TVU or refractory to medical treatment
	Heavy menstrual bleeding with fibroids or an abnormal endometrium on TVU or refractory to medical treatment
	Postpartum bleeding with suspected chronic retained products of conception or arteriovenous malformation on TVU
Reproductive problemsb
	Subfertility associated with an abnormal ultrasound or hysterosalpingogram
	Late miscarriage/preterm labour
Other
	Glandular abnormalities on cervical smear
	Identification (and retrieval) of lost intrauterine devices
	Incidental finding of an abnormal uterine cavity on TVU (mass, fluid etc.)
aHysteroscopy is only indicated under general or regional anaesthesia as day-cases where the outpatient setting has failed and the indication remains sufficiently strong (i.e. benefits of diagnostic information outweigh potential risks); patient preference; virginal women and some cardiac conditions where normal responses to vaso-vagal reactions are blunted. 
bThe role of hysteroscopy in investigating reproductive problems such as subfertility or recurrent pregnancy loss is contentious. There is some evidence from small RCTs that the use of hysteroscopy prior to in-vitro fertilisation cycles in women with previously failed cycles of treatment may improve pregnancy rates by up to 60%. The European multicentre ‘Trophy’ RCT5 is currently evaluating whether outpatient hysteroscopy does indeed confer an advantage, although the reasons why it might remain unclear.








PAGE  



1



